科兴生物制药股份有限公司 独立董事提名人声明与承诺 提名人深圳科益医药控股有限公司，现提名 HE RUYI（何如意）为科兴生 物制药股份有限公司第三届董事会独立董事候选人，并已充分了解被提名人职业、 学历、职称、详细的工作经历、全部兼职、有无重大失信等不良记录等情况。被 提名人已书面同意出任科兴生物制药股份有限公司第三届董事会独立董事候选 人（参见该独立董事候选人声明）。提名人认为，被提名人具备独立董事任职资 格，与科兴生物制药股份有限公司之间不存在任何影响其独立性的关系，具体声 明并承诺如下： 一、被提名人具备上市公司运作的基本知识，熟悉相关法律、行政法规、 规章及其他规范性文件，具有五年以上法律、经济、会计、财务、管理等履行独 立董事职责所必需的工作经验。 被提名人已经参加培训并取得证券交易所认可的相关培训证明材料。 二、被提名人任职资格符合下列法律、行政法规和部门规章的要求： （一）《中华人民共和国公司法》等关于董事任职资格的规定； （二）《中华人民共和国公务员法》关于公务员兼任职务的规定（如适用）； （三）中国证监会《上市公司独立董事管理办法》、上海证券交易所自律监 管规则以及公司章程有关独立董事任职 ...

证券代码：688136 证券简称：科兴制药 公告编号：2025-053 科兴生物制药股份有限公司 关于董事会换届选举的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 科兴生物制药股份有限公司（以下简称"公司"）第二届董事会任期已届满， 根据《中华人民共和国公司法》（以下简称"《公司法》"）《上海证券交易所 科创板股票上市规则》《上海证券交易所科创板上市公司自律监管指引第1号— —规范运作》等法律法规、规范性文件以及《公司章程》等规定，公司开展董事 会换届选举工作。现将相关情况公告如下： 一、董事会换届选举情况 经公司董事会提名委员会资格审核通过，公司于 2025 年 7 月 27 日召开第二 届董事会第二十七次会议，审议通过了《关于取消监事会、变更注册资本暨修订 <公司章程>的议案》《关于董事会换届选举暨提名第三届董事会非独立董事的 议案》《关于董事会换届选举暨提名第三届董事会独立董事的议案》，上述议案 尚需提交公司股东大会审议。 根据董事会审议通过的决议，公司本次换届同步修订《公司章程》，调整董 事会成员组成。调整 ...

证券代码：688136 证券简称：科兴制药 公告编号：2025-051 科兴生物制药股份有限公司 第二届监事会第二十三次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 科兴生物制药股份有限公司（以下简称"公司"）第二届监事会第二十三 次会议于 2025 年 7 月 27 日以现场结合通讯表决的方式召开。会议通知已于 2025 年 7 月 24 日发出。本次会议应出席监事 3 人，实际出席监事 3 人。 会议由监事会主席江海燕主持。会议召开符合有关法律、法规、规章和《公 司章程》的规定。 二、监事会会议审议情况 （一）审议通过《关于取消监事会、变更注册资本暨修订<公司章程>的议 案》 公司监事会认为：本次公司拟取消监事会、修订《公司章程》的事项系公司 为全面贯彻落实最新法律、法规及规范性文件要求，结合公司实际情况和业务发 展需要做出的决定，有利于进一步完善公司治理结构、更好地满足公司经营发展 需求。该事项符合《公司法》《上市公司章程指引》等法律、法规及规范性文件 的规定，不存在损害股东特 ...

证券代码：688136 证券简称：科兴制药 公告编号：2025-050 科兴生物制药股份有限公司 第二届董事会第二十七次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 科兴生物制药股份有限公司（以下简称"公司"）第二届董事会第二十七次 会议于 2025 年 7 月 27 日在深圳市南山区创益科技大厦 B 栋 19 楼会议室以现场 结合通讯的方式召开。本次会议通知于 2025 年 7 月 24 日通过邮件的方式送达各 位董事。本次会议应出席董事 7 人，实际出席董事 7 人。 会议由董事长邓学勤主持，公司监事，部分高管列席会议。会议召开符合有 关法律、法规、规章和《公司章程》的规定，会议决议合法、有效。 二、董事会会议审议情况 经各位董事认真审议，会议形成了如下决议： （二）审议通过《关于修订公司治理制度的议案》 为了进一步完善公司治理结构，促进公司规范运作，根据最新的《中华人民 共和国公司法》、《上海证券交易所科创板股票上市规则》等法律法规的相关规 定，结合公司实际情况，拟修订、制定公 ...

Core Insights - The report maintains a positive outlook on small molecule drug conjugates (SMDCs) and related companies, highlighting their potential in cancer treatment due to their ability to enhance efficacy while reducing toxicity [1][5][17] - The report emphasizes the clinical advantages of SMDCs, including better tumor penetration, reduced toxicity to normal cells, and easier control over synthesis and costs compared to antibody-drug conjugates (ADCs) [5][11][12] - The report identifies domestic biopharmaceutical companies, particularly Affinivax, as leaders in the SMDC space, showcasing significant advancements in innovative cancer drug development [5][12][17] Industry Overview - The pharmaceutical and biotechnology sector has shown a relative price-to-earnings (P/E) ratio of 51.14 as of July 25, 2025, which is significantly higher than its historical low of 24.38, indicating a premium valuation compared to the broader market [19] - The report notes that the healthcare sector's valuation is 279% higher than the Shanghai Composite Index, reflecting strong investor interest and confidence in the industry [19] - Recent market performance indicates a 1.90% increase in the pharmaceutical and biotechnology sector from July 21 to July 25, 2025, ranking it 16th among 27 sub-industries [26][29] Company Focus - The report suggests monitoring companies involved in the SMDC space, including Affinivax, and those collaborating with them, such as Innovent Biologics and others, which are expected to benefit from the growing interest in innovative cancer therapies [5][17][18] - Specific companies highlighted for their innovative drug development capabilities include Innovent Biologics, Shunyi Pharmaceutical, and others, which are positioned to capitalize on the advancements in SMDC technology [5][18]

Investment Rating - Industry rating is maintained at "Outperform the Market" [2] Core Insights - The global autoimmune disease treatment market is projected to exceed $100 billion, with an estimated market size of approximately $107.9 billion in 2024, expected to grow to $137.59 billion by 2033. The prevalence of autoimmune diseases is estimated to affect about 7.6% to 9.4% of the global population, leading to a long-term medication requirement for patients [3] - The leading drug in the autoimmune market for 2024 is Dupilumab, with sales of $14.2 billion, reflecting a year-on-year growth of 23%. The highest clinical demand is noted for atopic dermatitis, chronic obstructive pulmonary disease, asthma, systemic lupus erythematosus, and inflammatory bowel disease, which have high prevalence rates and complex disease courses [3] - Significant growth in overseas licensing for China's autoimmune sector is observed, with a total transaction amount of $9.132 billion from 2017 to 2024, where 2024 alone accounts for $3.108 billion, representing about one-third of the total, showing a notable increase compared to previous years [4] - Major business development transactions include Roche's acquisition of Telavant for $7.1 billion, Pfizer's acquisition of Arena for approximately $6.7 billion, and Takeda's acquisition of Nimbus for $4 billion, highlighting the substantial deal sizes in the autoimmune sector [4] Recommendations - Companies to watch include Yifang Bio, TianKang, CloudTop, Kexing Pharmaceutical, Zai Lab, Hengrui Medicine, Kangzhe Pharmaceutical, Sanofi, Innovent Biologics, Xiansheng Pharmaceutical, Lizhu Group, Zhixiang Jintai, China Antibody, and Chuanxin Biotech [5]

Core Viewpoint - The innovative drug sector is expected to thrive in 2025, with significant capital inflow and a focus on products with overseas potential, leading to substantial stock price increases in this segment [1][3]. Group 1: Market Performance - From early 2025 to date, the innovative drug sector has seen an average increase of over 50%, with nearly 50 stocks rising more than 30% [1]. - The Hongtu Innovation Healthcare Fund has achieved a cumulative increase of nearly 64% since early 2025, outperforming the industry [1][5]. - Historical performance of the Hongtu Innovation Healthcare Fund shows a year-to-date return of 63.66%, ranking 92 out of 594 funds [2]. Group 2: Industry Trends - The long-term development trend of China's innovative drug sector remains strong, supported by national strategies and favorable capital market policies [3]. - The market for innovative drugs in China is projected to exceed 250 billion RMB in 2024, with expectations to grow to approximately 450 billion RMB by 2030 [3]. - The overall market size, including all aspects of the drug development chain, is expected to approach 5.5 trillion RMB by 2024 and surpass 20 trillion RMB by 2030 [3]. Group 3: Investment Strategy - The investment strategy of the Hongtu Innovation Healthcare Fund focuses on high-elasticity innovative drug companies, particularly those with significant clinical breakthroughs and potential for international market entry [7][11]. - Key investment targets include companies with promising clinical data and those that are expected to achieve commercial success through domestic market integration and overseas licensing [7][10]. - The fund manager has successfully captured structural opportunities in the pharmaceutical sector, leading to superior long-term performance compared to peers [12]. Group 4: Notable Stocks - Major holdings in the Hongtu Innovation Healthcare Fund include companies like Xinlitai, Shutaishen, and Yifang Biotechnology, which have shown significant price increases and promising clinical data [8][9]. - The fund emphasizes investments in companies with first-in-class (FIC) and best-in-class (BIC) potential, focusing on those that can disrupt current clinical supply [11][12]. Group 5: Future Outlook - The innovative drug sector is expected to continue its upward trajectory, driven by overseas licensing opportunities and supportive domestic policies [12]. - The ongoing global business development (BD) transactions and key clinical data releases are anticipated to catalyze further growth in high-value innovative drug companies [12].

Fundraising Overview - The company has successfully completed its initial public offering (IPO) of 49.6753 million shares at a price of RMB 22.33 per share, raising a total of RMB 1,109,249,449, with a net amount of RMB 994,640,919 after deducting issuance costs [1][2] Fund Management and Regulatory Compliance - The company has established a special account for the management of the raised funds and signed a tripartite supervision agreement with the sponsor and the bank where the funds are deposited [2][3] - The agreement aims to ensure the proper use of funds for the "R&D Center Upgrade Project" and prohibits the use of these funds for any other purposes [3][4] Account Opening and Agreement Details - A new fundraising special account has been opened at China Postal Savings Bank, and the agreement includes provisions for the management and supervision of the funds [3][4] - The agreement specifies that the company can store part of the funds in deposits but cannot directly withdraw from these deposits [4][5] Supervision and Reporting - The sponsor is responsible for ongoing supervision of the fund management, including conducting at least biannual inspections of the fund's storage and usage [4][5] - The company must notify the sponsor of any significant expenditures from the special account and provide necessary documentation [5]

证券代码：688136 证券简称：科兴制药 公告编号：2025-049 科兴生物制药股份有限公司 关于开立募集资金专项账户并签订募集资金专户存储三方监管协议 的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、募集资金基本情况 经中国证券监督管理委员会出具的《关于同意科兴生物制药股份有限公司首 次公开发行股票注册的批复》（证监许可[2020]2655号）同意，科兴生物制药股 份有限公司（以下简称"公司"）首次公开发行人民币普通股4,967.5300万股， 每股面值人民币1.00元，每股发行价为人民币22.33元，本次发行募集资金总额 为1,109,249,449.00元，扣除保荐承销等发行费用114,608,529.84元，募集资金 净额为994,640,919.16元。上述募集资金已全部到位，经大华会计师事务所（特 殊普通合伙）验资，并于2020年12月7日出具大华验字[2020]000752号《验资报 告》验证确认。 上述募集资金到账后，公司依照规定对上述募集资金进行专户存储管理，并 与保荐机构中信建投证券股份 ...

Core Viewpoint - The AI Fund Penghua Pension Industry Stock (000854) reported a profit of 41.95 million yuan for Q2 2025, with a weighted average profit per fund share of 0.2136 yuan, and a net value growth rate of 9.71% during the reporting period [3]. Fund Performance - As of July 17, the fund's unit net value was 2.716 yuan, with a fund size of 464 million yuan [3][16]. - The fund's performance over different time frames includes a 23.34% growth rate over the last three months, ranking 12 out of 167 comparable funds; a 38.93% growth rate over the last six months, ranking 2 out of 167; a 35.39% growth rate over the last year, ranking 30 out of 166; and a -14.91% growth rate over the last three years, ranking 100 out of 159 [4]. Investment Strategy - The fund manager indicated a strong focus on innovative pharmaceuticals since the end of 2022, maintaining a high position despite market fluctuations, which contributed to significant gains in this sector [3]. - The average stock position over the last three years was 84.94%, compared to the industry average of 87.96%, with the highest position reaching 94.75% in Q1 2019 and the lowest at 73.24% in Q3 2021 [15]. Risk Metrics - The fund's Sharpe ratio over the last three years was -0.2327, ranking 133 out of 159 comparable funds [10]. - The maximum drawdown over the last three years was 44.66%, with the largest single-quarter drawdown occurring in Q1 2021 at 25.48% [12]. Top Holdings - As of Q2 2025, the fund's top ten holdings included companies such as BeiGene, Hengrui Medicine, and Dizhihua Pharmaceutical, among others [19].